Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients
暂无分享,去创建一个
E. Berns | B. Iacopetta | B. Powell | R. Seshadri | H. Elsaleh | G. Gnanasampanthan | F. Grieu | S. Bydder
[1] M. Pierotti,et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Piccart,et al. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] R. Vossen,et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. , 2000, Cancer research.
[4] B. Iacopetta,et al. Routine analysis of p53 mutation in clinical breast tumor specimens using fluorescence-based polymerase chain reaction and single strand conformation polymorphism. , 2000, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[5] B. Iacopetta,et al. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] J. Cunningham,et al. A prospective trial of midwest breast cancer patients: A p53 gene mutation is the most important predictor of adverse outcome , 2000, International journal of cancer.
[7] P. Chappuis,et al. Prognostic significance of p53 mutation in breast cancer: Frequent detection of non‐missense mutations by yeast functional assay , 1999, International journal of cancer.
[8] C Caldas,et al. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis , 1999, British Journal of Cancer.
[9] G. Hortobagyi,et al. Recent developments in breast cancer therapy. , 1999, Seminars in oncology.
[10] M. Gnant,et al. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. , 1999, European journal of cancer.
[11] F. Monti,et al. Prognosis and prediction of response in breast cancer: the current role of the main biological markers , 1998, Cell proliferation.
[12] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[13] M. Clarke,et al. Meta-analyses, multivariate analyses, and coping with the play of chance , 1998, The Lancet.
[14] B. Iacopetta,et al. Detection of p53 gene mutation by rapid PCR‐SSCP and its association with poor survival in breast cancer , 1997, International journal of cancer.
[15] C. de Toma,et al. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] B. Iacopetta,et al. A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[17] T. Aas,et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.
[18] D. Horsfall,et al. Relationship between p53 gene abnormalities and other tumour characteristics in breast‐cancer prognosis , 1996, International journal of cancer.
[19] L. Holmberg,et al. p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] L. Holmberg,et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.
[21] M. Espié,et al. p53 mutations and overexpression in locally advanced breast cancers. , 1994, British Journal of Cancer.
[22] M. Gnant,et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.